Dabur India Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Dabur India Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $1.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Dabur India Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $1.9M Trade | TransData Nexus

Dabur India Limited

Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $1.9M Total Trade · DGFT Verified

Dabur India Limited is an Indian pharmaceutical exporter with a total trade value of $1.9M across 6 products in 1 therapeutic categories. Based on 830 verified export shipments from Indian Customs (DGFT) records, Dabur India Limited is the #1 Indian exporter in 3 products including Extract, Arishta, Gutika. Top exports include Extract ($1.1M), Arishta ($590.0K), Churna ($111.2K).

Dabur India Limited — Export Portfolio & Destination Treemap

Dabur India Limited pharmaceutical export portfolio — 6 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Dabur India Limited? — Company Overview & Market Position

Dabur India Limited, established in 1884 by Dr. S.K. Burman in Kolkata, India, has evolved into a leading multinational consumer goods company specializing in Ayurvedic and natural health care products. The company is headquartered in Ghaziabad, Uttar Pradesh, and operates under the Corporate Identification Number (CIN) L24230UP1986PLC008119. As of March 2020, Dabur employed approximately 7,740 individuals. In the fiscal year ending March 31, 2025, Dabur reported revenues of approximately $1.5 billion, reflecting a 1.3% increase from the previous year. The company's diverse product portfolio includes health supplements, digestive products, hair care, oral care, skin care, home care, and food & beverages, marketed under well-known brands such as Dabur Chyawanprash, Dabur Honey, Dabur Amla, and Real.

What Does Dabur India Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Extract$1.1M 2Arishta$590.0K

Product Portfolio — Top 6 by Export Value

Dabur India Limited exports 6 pharmaceutical products across 1 therapeutic categories. Market leader (#1 exporter) in 3 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Extract	Ayurvedic & Herbal Products	$1.1M	126	9.0%	1
2	Arishta	Ayurvedic & Herbal Products	$590.0K	272	41.0%	1
3	Churna	Ayurvedic & Herbal Products	$111.2K	122	6.2%	5
4	Asava	Ayurvedic & Herbal Products	$61.3K	128	13.4%	2
5	Bhasma	Ayurvedic & Herbal Products	$33.8K	106	8.2%	4
6	Gutika	Ayurvedic & Herbal Products	$32.4K	76	25.9%	1

Dabur India Limited exports 6 pharmaceutical products across 1 therapeutic categories with a total export value of $1.9M. The company is the #1 Indian exporter in 3 products: Extract, Arishta, Gutika. The top category is Ayurvedic & Herbal Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 98.3% of total export value.

Dabur India Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Dabur India Limited operates a comprehensive manufacturing network spanning nine countries, including India, the UAE, Nepal, Bangladesh, Sri Lanka, South Africa, Nigeria, Egypt, and Turkey. This extensive network ensures the efficient production and distribution of its products across 120+ countries. In January 2024, the company approved an investment of ₹135 crore to establish a new manufacturing facility in South India, marking its first plant in the region. This facility is expected to produce a range of Dabur's Ayurvedic healthcare, personal care, and home care products, including Dabur Honey, Dabur Red Paste, and Odonil air fresheners.

3Key Leadership

Dabur India Limited is led by a team of experienced executives. Mohit Malhotra serves as the Chief Executive Officer (CEO) and Whole Time Director, overseeing the company's global operations. Ankush Jain holds the position of Chief Financial Officer (CFO), responsible for managing the company's financial strategies and operations. Pritam Das Narang serves as the Group Director of Corporate Affairs and Whole Time Director, focusing on corporate governance and strategic initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Dabur India Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Dabur India Limited has established a significant presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan. The company exports a diverse range of finished pharmaceutical formulations, including extracts, arishta, churna, asava, and bhasma, primarily in the Ayurvedic and herbal product categories. In the fiscal year 2022-2026, Dabur's total export value was $1.9 million USD, with 830 shipments across six products in one therapeutic category. The top five exported products were extract ($1.1 million, 9.0% market share), arishta ($590,000, 41.0% market share), churna ($111,000, 6.2% market share), asava ($61,000, 13.4% market share), and bhasma ($34,000, 8.2% market share). The company's portfolio concentration is high, with the top five products accounting for 98.3% of the total export value. Dabur's strong market position in these categories underscores its commitment to quality and regulatory compliance in these regions.

2Emerging Markets

Dabur India Limited has strategically expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are available in over 120 countries, with significant presence in the Middle East, SAARC countries, Africa, the US, Europe, and Russia. Dabur's commitment to quality and adherence to international standards have facilitated its entry into these markets, enabling the company to cater to diverse consumer needs and preferences.

Dabur India Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Dabur India Limited has made significant strides in the U.S. market, particularly in the dietary supplements segment. The company has established FDA facility registrations for its manufacturing plants, ensuring compliance with U.S. regulations. Dabur's products are manufactured in facilities that adhere to Good Manufacturing Practices (GMP), and the company has filed Abbreviated New Drug Applications (ANDAs) for certain products. While specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed, Dabur's commitment to quality and regulatory compliance is evident in its operations.

2WHO & EU GMP

Dabur India Limited's manufacturing facilities are certified for compliance with World Health Organization (WHO) Good Manufacturing Practices (GMP) and European Union (EU) GMP standards. These certifications reflect the company's adherence to international quality standards, ensuring the safety and efficacy of its products. Dabur's commitment to quality is further demonstrated by its extensive research and development efforts, which have led to the launch of new products such as the SIENS range of digital-first wellness products in June 2025.

3CDSCO & Indian Regulatory

Dabur India Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Dabur India Limited faces competition from several key players in the Ayurvedic and natural health care segment, including Himalaya Drug Company, Patanjali Ayurved, and Baidyanath. In the global market, competitors such as Himalaya and Patanjali have established significant market shares. Dabur's focus on quality, innovation, and extensive distribution network has enabled it to maintain a leading position in the industry. The company's diverse product portfolio and strong brand recognition contribute to its competitive edge.

2Key Differentiators

Dabur India Limited's key differentiators include its extensive experience of over 140 years in the Ayurvedic and natural health care sector, a diverse product portfolio encompassing health supplements, personal care, and food & beverages, and a strong commitment to quality and innovation. The company's ability to blend traditional Ayurvedic knowledge with modern science allows it to develop products tailored to the specific needs of consumers across the globe.

3Strategic Position

Dabur India Limited's current strategic direction focuses on expanding its presence in both domestic and international markets, with a particular emphasis on emerging markets. The company's investment in new manufacturing facilities, such as the recent establishment in South India, reflects its commitment to meeting local demand and enhancing supply chain efficiency. Dabur's future outlook includes further diversification of its product portfolio, exploration of new market segments, and continued emphasis on research and development to drive growth and innovation.

Buyer Due Diligence Brief — Evaluating Dabur India Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Dabur India Limited has a strong track record in manufacturing and exporting pharmaceutical formulations, with a total export value of $1.9 million USD and 830 shipments in the fiscal year 2022-2026. The company's portfolio concentration is high, with the top five products accounting for 98.3% of the total export value. Dabur's adherence to international quality standards, as evidenced by its WHO and EU GMP certifications, and its commitment to innovation and quality, make it a reliable supplier in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications when considering Dabur India Limited as a supplier:

FDA Facility Registration: Confirm that Dabur's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA).

WHO-GMP Certification: Ensure that Dabur's facilities comply with World Health Organization Good Manufacturing Practices.

Frequently Asked Questions — Dabur India Limited

How many pharmaceutical products does Dabur India Limited export from India?

Dabur India Limited exports 6 pharmaceutical products across 1 therapeutic categories. The top exports are Extract ($1.1M), Arishta ($590.0K), Churna ($111.2K), Asava ($61.3K), Bhasma ($33.8K). Total export value is $1.9M.

What is Dabur India Limited's total pharmaceutical export value?

Dabur India Limited's total pharmaceutical export value is $1.9M, based on 830 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Dabur India Limited the #1 Indian exporter?

Dabur India Limited is the #1 Indian exporter in 3 products: Extract (9.0% market share), Arishta (41.0% market share), Gutika (25.9% market share).

What therapeutic categories does Dabur India Limited cover?

Dabur India Limited exports across 1 therapeutic categories. The largest are Ayurvedic & Herbal Products (100.0%, 6 products).

Get Full Dabur India Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.